Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9703253 | 0.76 | MAPT (0.50) | KDM4EALDH1A1SMN1; SMN2HPGDMAPT | |
| SCHEMBL9704471 | 0.74 | MAPT (0.48) | KDM4EALDH1A1SMN1; SMN2MAPTAPEX1 | |
| SCHEMBL13948933 | 0.74 | MKNK1 (0.60) | KDM4EALDH1A1SMN1; SMN2MAPTAPEX1 | |
| SCHEMBL19574781 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1MAPTAPEX1RECQL | |
| SCHEMBL12445185 | 0.72 | MAPT (0.65) | KDM4EALDH1A1SMN1; SMN2HPGDMAPT | |
| SCHEMBL7076189 | 0.71 | MKNK1 (0.56) | KDM4EALDH1A1SMN1; SMN2MAPTAPEX1 | |
| SCHEMBL14511179 | 0.70 | MAPT (0.68) | KDM4EALDH1A1SMN1; SMN2HPGDMAPT | |
| SCHEMBL31156527 | 0.69 | MAPKAPK2 (0.51) | KDM4EALDH1A1SMN1; SMN2HPGDMAPT | |
| SCHEMBL1257032 | 0.69 | MAPKAPK2 (0.51) | KDM4EALDH1A1SMN1; SMN2HPGDMAPT | |
| SCHEMBL15430823 | 0.69 | AHR (0.57) | KDM4EALDH1A1MAPTAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | claimed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | claimed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | claimed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-0880353-A4 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS INC (US) | 2001-04-18 | — | — | EP | disclosed |
| US-5998423-A | IN SKIN OR HAIR; ADMINISTERING ADENOSINE RECEPTOR ANTAGONIST | THERASYS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0880353-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | Therasys, Inc. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998015276-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS, INC. (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | KDM4E 4617/4885ALDH1A1 336/4885SMN1; SMN2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.